A review of vaccine research and development: the human immunodeficiency virus (HIV).

Since the discovery of AIDS in 1981, the global spread of HIV has reached pandemic proportions, representing a global developmental and public health threat. The development of a safe, globally effective and affordable HIV vaccine offers the best hope for the future control of the pandemic. Significant progress has been made over the past years in the areas of basic virology, immunology, pathogenesis of HIV/AIDS and the development of antiretroviral drugs. However, the development of an HIV vaccine faces formidable scientific challenges related to the high genetic variability of the virus, the lack of immune correlates of protection, limitations with the existing animal models and logistical problems associated with the conduct of multiple clinical trials. More than 35 vaccine candidates have been tested in Phase I/II clinical trials, involving more than 10,000 volunteers, and two Phase III trials have been completed, themselves involving more than 7500 volunteers. Multiple vaccine concepts and vaccination strategies have been tested, including DNA vaccines, subunit vaccines, live vectored recombinant vaccines and various prime-boost vaccine combinations. This article reviews the state of the art in HIV vaccine development, summarizes the results obtained so far and discusses the challenges to be met in the development of the various vaccine candidates.

[1]  J. Heeney.  Primate models for AIDS vaccine development , 1996, AIDS.

[2]  Y. Balabanova,et al.  Tuberculosis, HIV seroprevalence and intravenous drug abuse in prisoners , 2005, European Respiratory Journal.

[3]  S. Kent,et al.  Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. , 2005, Vaccine.

[4]  Dennis R. Burton,et al.  Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design , 2003, Journal of Virology.

[5]  M. Kieny,et al.  Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 , 1995, Journal of virology.

[6]  D. Montefiori,et al.  Protection by Live, Attenuated Simian Immunodeficiency Virus against Heterologous Challenge , 1999, Journal of Virology.

[7]  Yiming Shao,et al.  Enhanced: The Need for a Global HIV Vaccine Enterprise , 2003, Science.

[8]  D. Harrich,et al.  Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development , 2003, Journal of Virology.

[9]  A. Lemckert,et al.  Challenges in the Search for an HIV Vaccine , 2003, European Journal of Epidemiology.

[10]  D. Trono,et al.  Hide, shield and strike back: how HIV-infected cells avoid immune eradication , 2003, Nature Reviews Immunology.

[11]  Todd M. Allen,et al.  Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen , 1999, Journal of Virology.

[12]  A. Burny,et al.  Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  B. M. Flynn,et al.  Role of CD8+ Lymphocytes in Control of Simian Immunodeficiency Virus Infection and Resistance to Rechallenge after Transient Early Antiretroviral Treatment , 2001, Journal of Virology.

[14]  A. Haase.  Perils at mucosal front lines for HIV and SIV and their hosts , 2005, Nature Reviews Immunology.

[15]  A. Lackner,et al.  HIV swiftly guts the immune system , 2005, Nature Medicine.

[16]  A. Lapedes,et al.  Timing the ancestor of the HIV-1 pandemic strains. , 2000, Science.

[17]  E. De Clercq,et al.  In Vivo Evolution of Human Immunodeficiency Virus Type 1 toward Increased Pathogenicity through CXCR4-Mediated Killing of Uninfected CD4 T Cells , 2003, Journal of Virology.

[18]  Philip R. Johnson,et al.  Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles , 2000, Journal of Virology.

[19]  D. Montefiori,et al.  Replicating Rather than Nonreplicating Adenovirus-Human Immunodeficiency Virus Recombinant Vaccines Are Better at Eliciting Potent Cellular Immunity and Priming High-Titer Antibodies , 2005, Journal of Virology.

[20]  J. Mascola,et al.  Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys , 2005, Journal of Virology.

[21]  A. Nicoll,et al.  The public health significance of HIV-1 subtypes , 2001, AIDS.

[22]  Todd M. Allen,et al.  Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques , 2001, Nature Medicine.

[23]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[24]  Norman L. Letvin,et al.  Magnitude and Diversity of Cytotoxic-T-Lymphocyte Responses Elicited by Multiepitope DNA Vaccination in Rhesus Monkeys , 2003, Journal of Virology.

[25]  Peter D. Kwong,et al.  Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope , 2004, Journal of Virology.

[26]  V. Bond,et al.  Extracellular Nef Protein Targets CD4+ T Cells for Apoptosis by Interacting with CXCR4 Surface Receptors , 2004, Journal of Virology.

[27]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[28]  F. E. McCutchan,et al.  In-Depth Analysis of a Heterosexually Acquired Human Immunodeficiency Virus Type 1 Superinfection: Evolution, Temporal Fluctuation, and Intercompartment Dynamics from the Seronegative Window Period through 30 Months Postinfection , 2005, Journal of Virology.

[29]  Jon Cohen.  AIDS Vaccine Trial Produces Disappointment and Confusion , 2003, Science.

[30]  M. Lifton,et al.  Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity , 2005, Journal of Virology.

[31]  B. Ensoli,et al.  Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. , 2004, Current opinion in biotechnology.

[32]  Qingsheng Li,et al.  Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells , 2005, Nature.

[33]  J. Levy,et al.  Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers , 2001, AIDS.

[34]  S. Zolla-Pazner,et al.  Vaccine Protection against a Heterologous, Non-Syncytium-Inducing, Primary Human Immunodeficiency Virus , 1998, Journal of Virology.

[35]  B. Berkhout,et al.  Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector , 2004, AIDS.

[36]  S. Kostense,et al.  Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 , 2004, The Journal of Immunology.

[37]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[38]  D. Montefiori,et al.  Induction of Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 Primary Isolates by Gag-Env Pseudovirion Immunization , 2005, Journal of Virology.

[39]  Q. Sattentau,et al.  Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. , 2004, Vaccine.

[40]  P. Sen,et al.  Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model , 2001, AIDS.

[41]  Y. Nagai,et al.  Rapid Appearance of Secondary Immune Responses and Protection from Acute CD4 Depletion after a Highly Pathogenic Immunodeficiency Virus Challenge in Macaques Vaccinated with a DNA Prime/Sendai Virus Vector Boost Regimen , 2001, Journal of Virology.

[42]  Q. Yao,et al.  Virus‐like particles as HIV‐1 vaccines , 2005, Reviews in medical virology.

[43]  K. Mansfield,et al.  Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus Monkeys , 2005, Journal of Virology.

[44]  K. Saksela,et al.  Human immunodeficiency virus type 1 Nef selectively associates with a catalytically active subpopulation of p21-activated kinase 2 (PAK2) independently of PAK2 binding to Nck or beta-PIX. , 2001, Journal of Virology.

[45]  Ingrid Markovic,et al.  Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. , 2004, Current HIV research.

[46]  G. Nabel.  HIV vaccine strategies. , 2002, Vaccine.

[47]  Gladys Mutangadura,et al.  The spread and effect of HIV-1 infection in sub-Saharan Africa , 2002, The Lancet.

[48]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[49]  T. Matano,et al.  Involvement of Multiple Epitope-Specific Cytotoxic T-Lymphocyte Responses in Vaccine-Based Control of Simian Immunodeficiency Virus Replication in Rhesus Macaques , 2006, Journal of Virology.

[50]  E. Rosenberg,et al.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.

[51]  D. Burton,et al.  GP120: target for neutralizing HIV-1 antibodies. , 2006, Annual review of immunology.

[52]  Q. Sattentau,et al.  Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins , 1998, Journal of Virology.

[53]  J. Berzofsky,et al.  Progress on new vaccine strategies against chronic viral infections. , 2004, The Journal of clinical investigation.

[54]  A. Craiu,et al.  Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[55]  B. Korber,et al.  Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. , 1998, The Journal of infectious diseases.

[56]  D. Weiner,et al.  DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade , 2004, Clinical Microbiology Reviews.

[57]  P. Earl,et al.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. , 2002, Vaccine.

[58]  Mark G. Lewis,et al.  Outcome of Simian-Human Immunodeficiency Virus Strain 89.6p Challenge following Vaccination of Rhesus Macaques with Human Immunodeficiency Virus Tat Protein , 2002, Journal of Virology.

[59]  Todd M. Allen,et al.  Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef , 1999, Nature Medicine.

[60]  D. Watkins,et al.  Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques , 2000, Nature Medicine.

[61]  Yong He,et al.  Human Immunodeficiency Virus (HIV) gp41 Escape Mutants: Cross-Resistance to Peptide Inhibitors of HIV Fusion and Altered Receptor Activation of gp120 , 2005, Journal of Virology.

[62]  Bette Korber,et al.  Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.

[63]  H. McClure,et al.  Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV. , 2002, Vaccine.

[64]  J. Mascola,et al.  Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins , 2005, Journal of Virology.

[65]  G. McGaughey,et al.  Progress towards the development of a HIV-1 gp41-directed vaccine. , 2004, Current HIV research.

[66]  D. Montefiori,et al.  Improved Protection of Rhesus Macaques against Intrarectal Simian Immunodeficiency Virus SIVmac251 Challenge by a Replication-Competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag Recombinant Priming/gp120 Boosting Regimen , 2003, Journal of Virology.

[67]  Bette T. Korber,et al.  Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein , 2005, Journal of Virology.

[68]  Philip J. R. Goulder,et al.  HIV-1 Viral Escape in Infancy Followed by Emergence of a Variant-Specific CTL Response1 , 2005, The Journal of Immunology.

[69]  M. Reitz,et al.  Expression and Characterization of a Single-Chain Polypeptide Analogue of the Human Immunodeficiency Virus Type 1 gp120-CD4 Receptor Complex , 2000, Journal of Virology.

[70]  B. Ensoli.  Rational vaccine strategies against AIDS: background and rationale. , 2005, Microbes and infection.

[71]  N. Haigwood,et al.  Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Christoph Grundner,et al.  Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. , 2003, Virology.

[73]  T. Wrin,et al.  Induction of Humoral Immune Responses following Vaccination with Envelope-Containing, Formaldehyde-Treated, Thermally Inactivated Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[74]  I. Chen,et al.  Formaldehyde-Treated, Heat-Inactivated Virions with Increased Human Immunodeficiency Virus Type 1 Env Can Be Used To Induce High-Titer Neutralizing Antibody Responses , 2005, Journal of Virology.

[75]  J. Binley,et al.  A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.

[76]  D. Trono,et al.  Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency , 1992, Journal of virology.

[77]  M. Wainberg,et al.  Construction and In Vitro Properties of a Series of Attenuated Simian Immunodeficiency Viruses with All Accessory Genes Deleted , 2001, Journal of Virology.

[78]  N. Haigwood,et al.  Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies , 2002, Journal of Virology.

[79]  K. Mansfield,et al.  Identifying the Target Cell in Primary Simian Immunodeficiency Virus (SIV) Infection: Highly Activated Memory CD4+ T Cells Are Rapidly Eliminated in Early SIV Infection In Vivo , 2000, Journal of Virology.

[80]  Jamie K. Scott,et al.  Identification and Characterization of a Peptide That Specifically Binds the Human, Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody b12 , 2001, Journal of Virology.

[81]  D. Montefiori,et al.  Crosslinked HIV-1 envelope–CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[82]  J. Heeney,et al.  Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine , 1999, Nature Medicine.

[83]  Todd M. Allen,et al.  HLA-B63 Presents HLA-B57/B58-Restricted Cytotoxic T-Lymphocyte Epitopes and Is Associated with Low Human Immunodeficiency Virus Load , 2005, Journal of Virology.

[84]  John P. Moore,et al.  Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2002, Journal of Virology.

[85]  Xiping Wei,et al.  Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus , 1997, Nature Medicine.

[86]  K. Clark,et al.  Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus , 1999, Gene Therapy.

[87]  S. Zolla-Pazner,et al.  Vaccination of Rhesus Macaques with Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Env V3 Elicits Neutralizing Antibody-Mediated Protection against Simian-Human Immunodeficiency Virus with a Homologous but Not a Heterologous V3 Motif , 2005, Journal of Virology.

[88]  David Montefiori,et al.  An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants , 2001, Cell.

[89]  D. Montefiori,et al.  Containment of Simian Immunodeficiency Virus Infection in Vaccinated Macaques: Correlation with the Magnitude of Virus-Specific Pre- and Postchallenge CD4+ and CD8+ T Cell Responses1 , 2002, The Journal of Immunology.

[90]  D. Weiner,et al.  Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination , 1997, Nature Medicine.

[91]  H. Clifford Lane,et al.  Administration of an Anti-CD8 Monoclonal Antibody Interferes with the Clearance of Chimeric Simian/Human Immunodeficiency Virus during Primary Infections of Rhesus Macaques , 1998, Journal of Virology.

[92]  S. Self,et al.  Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. , 2001, The Journal of infectious diseases.

[93]  H. McClure,et al.  Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation , 2003, AIDS.

[94]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[95]  Y. Kawaoka,et al.  Vaccination with a Recombinant Vesicular Stomatitis Virus Expressing an Influenza Virus Hemagglutinin Provides Complete Protection from Influenza Virus Challenge , 1998, Journal of Virology.

[96]  R. Pal,et al.  Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. , 1996, Virology.

[97]  D. Birx,et al.  HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. , 2004, Tissue antigens.

[98]  R. Steinman,et al.  Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[99]  N. Imami,et al.  The challenge of developing an effective HIV-1 vaccine , 2004 .

[100]  M. Alizon,et al.  HIV-1 entry and how to block it. , 2001, AIDS.

[101]  R. Steinman,et al.  The Simian Immunodeficiency Virus Δnef Vaccine, after Application to the Tonsils of Rhesus Macaques, Replicates Primarily within CD4+ T Cells and Elicits a Local Perforin-Positive CD8+ T-Cell Response , 2002, Journal of Virology.

[102]  Alessandro Sette,et al.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia , 2000, Nature.

[103]  Susan Zolla-Pazner,et al.  Identifying epitopes of HIV-1 that induce protective antibodies , 2004, Nature Reviews Immunology.

[104]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[105]  Q. Sattentau,et al.  Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Line–adapted HIV-1 Neutralization , 1997, The Journal of experimental medicine.

[106]  D. Watkins,et al.  Immunization of Rhesus Macaques with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen Induces Broad Simian Immunodeficiency Virus (SIV)-Specific T-Cell Responses and Reduces Initial Viral Replication but Does Not Prevent Disease Progression following Challenge with Pathogenic SIVmac239 , 2002, Journal of Virology.

[107]  G. Spear,et al.  Induction of Mucosal and Systemic Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 (HIV-1) by Oral Immunization with Bovine Papillomavirus-HIV-1 gp41 Chimeric Virus-Like Particles , 2004, Journal of Virology.

[108]  S. Rowland-Jones,et al.  Cellular immune responses to HIV , 2001, Nature.

[109]  K. Reimann,et al.  Variability of Viral Load in Plasma of Rhesus Monkeys Inoculated with Simian Immunodeficiency Virus or Simian-Human Immunodeficiency Virus: Implications for Using Nonhuman Primate AIDS Models To Test Vaccines and Therapeutics , 2001, Journal of Virology.

[110]  E A Emini,et al.  Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. , 1997, AIDS research and human retroviruses.

[111]  T. Mor,et al.  A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[112]  R. Andino,et al.  Protection against Simian Immunodeficiency Virus Vaginal Challenge by Using Sabin Poliovirus Vectors , 2001, Journal of Virology.

[113]  B. Korber,et al.  Evolutionary and immunological implications of contemporary HIV-1 variation. , 2001, British medical bulletin.

[114]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[115]  Gennaro Ciliberto,et al.  Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. , 2003, Journal of molecular biology.

[116]  J. Mascola,et al.  Characterization of Antibody Responses Elicited by Human Immunodeficiency Virus Type 1 Primary Isolate Trimeric and Monomeric Envelope Glycoproteins in Selected Adjuvants , 2006, Journal of Virology.

[117]  Steven M. Wolinsky,et al.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes , 2002, Nature.

[118]  R. Compans,et al.  Enhancement of Mucosal Immunization with Virus-Like Particles of Simian Immunodeficiency Virus , 2003, Journal of Virology.

[119]  S. Wain-Hobson,et al.  Simian Immunodeficiency Virus Promoter Exchange Results in a Highly Attenuated Strain That Protects against Uncloned Challenge Virus , 2004, Journal of Virology.

[120]  F. Gao,et al.  Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes , 1999, Nature.

[121]  L. Stamatatos,et al.  Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate , 2003, Journal of Virology.

[122]  B. Gazzard,et al.  A Balanced Type 1/Type 2 Response Is Associated with Long-Term Nonprogressive Human Immunodeficiency Virus Type 1 Infection , 2002, Journal of Virology.

[123]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[124]  Kendall C. Krebs,et al.  Cytotoxic T-Lymphocyte Escape Does Not Always Explain the Transient Control of Simian Immunodeficiency Virus SIVmac239 Viremia in Adenovirus-Boosted and DNA-Primed Mamu-A*01-Positive Rhesus Macaques , 2005, Journal of Virology.

[125]  M. Ciccozzi,et al.  The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. , 2005, The Journal of infectious diseases.

[126]  B. M. Flynn,et al.  Containment of Simian Immunodeficiency Virus Infection: Cellular Immune Responses and Protection from Rechallenge following Transient Postinoculation Antiretroviral Treatment , 2000, Journal of Virology.

[127]  Mary J. Connell,et al.  Novel Adeno-Associated Virus Vector Vaccine Restricts Replication of Simian Immunodeficiency Virus in Macaques , 2005, Journal of Virology.

[128]  R P Johnson,et al.  Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. , 1998, Science.

[129]  Christopher J. Miller,et al.  Retroviral Recombination In Vivo: Viral Replication Patterns and Genetic Structure of Simian Immunodeficiency Virus (SIV) Populations in Rhesus Macaques after Simultaneous or Sequential Intravaginal Inoculation with SIVmac239Δvpx/Δvpr and SIVmac239Δnef , 2005, Journal of Virology.

[130]  J. Berzofsky,et al.  Mucosal AIDS vaccines: current status and future directions , 2004, Expert review of vaccines.

[131]  P. Vernazza,et al.  Sexual transmission of HIV: infectiousness and prevention. , 1999, AIDS.

[132]  John P. Moore,et al.  AIDS vaccine models: Challenging challenge viruses , 2002, Nature Medicine.

[133]  Todd M. Allen,et al.  Understanding cytotoxic T‐lymphocyte escape during simian immunodeficiency virus infection , 2001, Immunological reviews.

[134]  D. Venzon,et al.  Potent, Persistent Induction and Modulation of Cellular Immune Responses in Rhesus Macaques Primed with Ad5hr-Simian Immunodeficiency Virus (SIV) env/rev, gag, and/or nef Vaccines and Boosted with SIV gp120 , 2003, Journal of Virology.

[135]  Shixia Wang,et al.  Application of the polyvalent approach to HIV-1 vaccine development. , 2005, Current drug targets. Infectious disorders.

[136]  D. Birx,et al.  HIV Vaccine Trial Justified , 2004, Science.

[137]  J. Carr,et al.  Diversity of envelope glycoprotein from human immunodeficiency virus type 1 of recent seroconverters in Thailand. , 2000, AIDS research and human retroviruses.

[138]  A. McMichael,et al.  Opinion — vaccines: The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? , 2002, Nature Reviews Immunology.

[139]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[140]  J. Shiver,et al.  Heterologous Human Immunodeficiency Virus Type 1 Priming-Boosting Immunization Strategies Involving Replication-Defective Adenovirus and Poxvirus Vaccine Vectors , 2004, Journal of Virology.

[141]  D. Palmer,et al.  Human immunodeficiency virus. , 1990, Journal of the American Podiatric Medical Association.

[142]  L. Stamatatos,et al.  Changes in the Immunogenic Properties of Soluble gp140 Human Immunodeficiency Virus Envelope Constructs upon Partial Deletion of the Second Hypervariable Region , 2003, Journal of Virology.

[143]  T. Hanke,et al.  MVA as a vector for vaccines against HIV-1 , 2004, Expert review of vaccines.

[144]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[145]  J. Shiver,et al.  Vectored Gag and Env but Not Tat Show Efficacy against Simian-Human Immunodeficiency Virus 89.6P Challenge in Mamu-A*01-Negative Rhesus Monkeys , 2005, Journal of Virology.

[146]  R. Desrosiers.  Prospects for an AIDS vaccine , 2004, Nature Medicine.

[147]  S. Staprans,et al.  The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines , 2004, Expert review of vaccines.

[148]  J. Berzofsky,et al.  Assessment of the relative therapeutic effects of vaccines on virus load and immune responses in small groups at several time points: efficacy of mucosal and subcutaneous polypeptide vaccines in rhesus macaques exposed to SHIV. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[149]  Peter D. Kwong,et al.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.

[150]  R. Gallo.  The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years , 2005, The Lancet.

[151]  J. Heeney,et al.  Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. , 2004, Vaccine.

[152]  J. Mascola,et al.  Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus , 2005, Journal of Virology.

[153]  J. Mascola,et al.  The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope , 2004, Journal of Virology.

[154]  G. Nabel.  Close to the Edge: Neutralizing the HIV-1 Envelope , 2005, Science.

[155]  Philip J. R. Goulder,et al.  HIV and SIV CTL escape: implications for vaccine design , 2004, Nature Reviews Immunology.

[156]  C. Beyrer,et al.  Human immunodeficiency virus vaccine development in developing countries: are efficacy trials feasible? , 2000, Journal of human virology.

[157]  Z. Grossman,et al.  HIV-1 Viremia Prevents the Establishment of Interleukin 2–producing HIV-specific Memory CD4+ T Cells Endowed with Proliferative Capacity , 2003, The Journal of experimental medicine.

[158]  J. Flamm,et al.  Severe CD4+ T-Cell Depletion in Gut Lymphoid Tissue during Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in Restoration following Highly Active Antiretroviral Therapy , 2003, Journal of Virology.

[159]  Y. Nagai,et al.  Protective Efficacy of an AIDS Vaccine, a Single DNA Priming Followed by a Single Booster with a Recombinant Replication-Defective Sendai Virus Vector, in a Macaque AIDS Model , 2003, Journal of Virology.

[160]  New hope for AIDS vaccine. , 2003, Lancet.

[161]  J. Schmitz,et al.  Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. , 1999, Journal of immunology.

[162]  D. Montefiori,et al.  Highly Attenuated Vaccine Strains of Simian Immunodeficiency Virus Protect against Vaginal Challenge: Inverse Relationship of Degree of Protection with Level of Attenuation , 1999, Journal of Virology.

[163]  J. Shiver,et al.  Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. , 2004, Annual review of medicine.

[164]  S. Kostense,et al.  Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.

[165]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[166]  S. Deeks,et al.  Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways. , 2005, Vaccine.

[167]  Wayne C Koff,et al.  HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.

[168]  R. M. Hendry,et al.  Neutralization of primary HIV‐1 isolates by anti‐envelope monoclonal antibodies , 1995, AIDS.

[169]  J. Levy,et al.  Multiepitopic B- and T-Cell Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine , 2000, Journal of Virology.

[170]  J. Sodroski,et al.  An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys , 1996, Journal of virology.

[171]  Christine Hogan,et al.  Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[172]  W. Weissenhorn,et al.  Trimeric Membrane-anchored gp41 Inhibits HIV Membrane Fusion* , 2005, Journal of Biological Chemistry.

[173]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[174]  A. Whatmore,et al.  Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence , 1995, Journal of virology.

[175]  H. McClure,et al.  Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques , 1999, Nature Medicine.

[176]  J. Guillet,et al.  Type 1 CD4+ T-Cell Help Is Required for Induction of Antipeptide Multispecific Cytotoxic T Lymphocytes by a Lipopeptidic Vaccine in Rhesus Macaques , 1999, Journal of Virology.

[177]  E. Rosenberg,et al.  Substantial Differences in Specificity of HIV-Specific Cytotoxic T Cells in Acute and Chronic HIV Infection , 2001, The Journal of experimental medicine.

[178]  B. Graham,et al.  Candidate AIDS vaccines. , 1995, The New England journal of medicine.

[179]  R. Moss,et al.  CD8+ T-Cell-Mediated Cross-Clade Protection in the Genital Tract following Intranasal Immunization with Inactivated Human Immunodeficiency Virus Antigen Plus CpG Oligodeoxynucleotides , 2005, Journal of Virology.

[180]  Z. Hel,et al.  Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model. , 2002, Vaccine.

[181]  H. Liao,et al.  Vaccine-Elicited V3 Loop-Specific Antibodies in Rhesus Monkeys and Control of a Simian-Human Immunodeficiency Virus Expressing a Primary Patient Human Immunodeficiency Virus Type 1 Isolate Envelope , 2001, Journal of Virology.

[182]  R. K. Evans,et al.  Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene , 2003, Journal of Virology.

[183]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[184]  G. Lewis,et al.  Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. , 2002, Vaccine.

[185]  Aki Manninen,et al.  Regulation of T cell activation by HIV-1 accessory proteins: Vpr acts via distinct mechanisms to cooperate with Nef in NFAT-directed gene expression and to promote transactivation by CREB. , 2003, Virology.

[186]  D. Watkins,et al.  Multispecific Vaccine-Induced Mucosal Cytotoxic TLymphocytes Reduce Acute-Phase Viral Replication but Fail inLong-Term Control of Simian Immunodeficiency VirusSIVmac239 , 2003, Journal of Virology.

[187]  Christoph Grundner,et al.  Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[188]  L. Foresman,et al.  Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS , 1997, Journal of virology.

[189]  D. Watkins,et al.  Repeated Low-Dose Mucosal Simian Immunodeficiency Virus SIVmac239 Challenge Results in the Same Viral and Immunological Kinetics as High-Dose Challenge: a Model for the Evaluation of Vaccine Efficacy in Nonhuman Primates , 2004, Journal of Virology.

[190]  S. Kent,et al.  Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus , 1998, Journal of Virology.

[191]  J. Lifson,et al.  Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. , 1998, AIDS research and human retroviruses.

[192]  P. Luciw,et al.  Characterization of Human Immunodeficiency Virus Gag-Specific Gamma Interferon-Expressing Cells following Protective Mucosal Immunization with Alphavirus Replicon Particles , 2005, Journal of Virology.

[193]  E. Tramont,et al.  The human immunodeficiency virus. , 1991, Dermatologic clinics.

[194]  Philip R. Johnson,et al.  HIV vaccine design: insights from live attenuated SIV vaccines , 2005, Nature Immunology.

[195]  R. Gavioli,et al.  Recent advances in the development of HIV-1 Tat-based vaccines. , 2004, Current HIV research.

[196]  Eun-Young Kim,et al.  Propagation and Dissemination of Infection after Vaginal Transmission of Simian Immunodeficiency Virus , 2005, Journal of Virology.

[197]  D. Weiner,et al.  Approaches for the design and evaluation of HIV-1 DNA vaccines , 2004, Expert review of vaccines.

[198]  R. Anderson,et al.  Potential public health impact of imperfect HIV type 1 vaccines. , 2005, The Journal of infectious diseases.

[199]  Todd M. Allen,et al.  Tat-Vaccinated Macaques Do Not Control Simian Immunodeficiency Virus SIVmac239 Replication , 2002, Journal of Virology.

[200]  T. Dubensky,et al.  An Alphavirus Replicon Particle Chimera Derived from Venezuelan Equine Encephalitis and Sindbis Viruses Is a Potent Gene-Based Vaccine Delivery Vector , 2003, Journal of Virology.

[201]  A. McPherson,et al.  Atomic Force Microscopy Investigation of Human Immunodeficiency Virus (HIV) and HIV-Infected Lymphocytes , 2003, Journal of Virology.

[202]  G. Goldstein.  HIV–1 Tat protein as a potential AIDS vaccine , 1996, Nature Medicine.

[203]  M. Tremblay,et al.  Presence of Host ICAM-1 in Human Immunodeficiency Virus Type 1 Virions Increases Productive Infection of CD4+ T Lymphocytes by Favoring Cytosolic Delivery of Viral Material , 2003, Journal of Virology.

[204]  M. Champe,et al.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 , 1990, Nature.

[205]  Mario Roederer,et al.  Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection , 2005, Nature.

[206]  J. Whitney,et al.  Live attenuated HIV vaccines: pitfalls and prospects , 2004, Current opinion in infectious diseases.

[207]  K. Saksela,et al.  Human Immunodeficiency Virus Type 1 Nef Selectively Associates with a Catalytically Active Subpopulation of p21-Activated Kinase 2 (PAK2) Independently of PAK2 Binding to Nck or β-PIX , 2001, Journal of Virology.

[208]  M. Kanekiyo,et al.  Priming-Boosting Vaccination with Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and a Nonreplicating Vaccinia Virus Recombinant Leads to Long-Lasting and Effective Immunity , 2005, Journal of Virology.

[209]  C. Cheng‐Mayer,et al.  Mucosal Transmission and Induction of Simian AIDS by CCR5-Specific Simian/Human Immunodeficiency Virus SHIVSF162P3 , 2001, Journal of Virology.

[210]  J. Mascola,et al.  Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates , 2005, Journal of Virology.

[211]  D. Watkins,et al.  Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag , 2005, Journal of Virology.

[212]  J. Sodroski,et al.  Characterization of the Outer Domain of the gp120 Glycoprotein from Human Immunodeficiency Virus Type 1 , 2004, Journal of Virology.

[213]  N. Letvin.  Strategies for an HIV vaccine. , 2002, The Journal of clinical investigation.

[214]  D. Ladant,et al.  Induction of Neutralizing Antibodies and Th1-Polarized and CD4-Independent CD8+ T-Cell Responses following Delivery of Human Immunodeficiency Virus Type 1 Tat Protein by Recombinant Adenylate Cyclase of Bordetella pertussis , 2005, Journal of Virology.

[215]  Gary J. Nabel,et al.  The need for a global HIV vaccine enterprise. Policy forum. , 2003 .

[216]  C. E. Parker,et al.  Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5 , 2001, Journal of Virology.

[217]  R. Compans,et al.  Mucosal Immunization with Virus-Like Particles of Simian Immunodeficiency Virus Conjugated with Cholera Toxin Subunit B , 2003, Journal of Virology.

[218]  R. Gallo.  Tat as one key to HIV-induced immune pathogenesis and Pat toxoid as an important component of a vaccine , 1999 .

[219]  S. Osmanov,et al.  Past, present and future of HIV vaccine trials in developing countries. , 2002, Vaccine.

[220]  G. Shaw,et al.  Risk to Human Health from a Plethora of Simian Immunodeficiency Viruses in Primate Bushmeat , 2002, Emerging infectious diseases.

[221]  Samir Mitragotri,et al.  Immunization without needles , 2005, Nature Reviews Immunology.

[222]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[223]  R. Steinman,et al.  In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.

[224]  D. Montefiori,et al.  Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[225]  M. Kieny,et al.  A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. , 1995, AIDS research and human retroviruses.

[226]  R. Siliciano,et al.  The challenge of viral reservoirs in HIV-1 infection. , 2002, Annual review of medicine.

[227]  A. Osterhaus,et al.  Vaccination with Rev and Tat against AIDS. , 1999, Vaccine.

[228]  Yunkai Yu,et al.  Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex , 2003, Science.

[229]  D. Weiner,et al.  Present status of human HIV vaccine development , 2003, AIDS.

[230]  Joseph Sodroski,et al.  Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. , 2002, AIDS research and human retroviruses.

[231]  J. Excler.  AIDS vaccine development: perspectives, challenges & hopes. , 2005, The Indian journal of medical research.

[232]  H. Katinger,et al.  The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.

[233]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[234]  G. Nabel,et al.  Enhanced Breadth of CD4 T-Cell Immunity by DNA Prime and Adenovirus Boost Immunization to Human Immunodeficiency Virus Env and Gag Immunogens , 2005, Journal of Virology.

[235]  W. Koff,et al.  Developing an AIDS Vaccine: Need, Uncertainty, Hope , 2004, Science.

[236]  Q. Sattentau,et al.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. , 1999, AIDS.

[237]  G Y Ishioka,et al.  Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. , 1999, Journal of immunology.

[238]  F. McCutchan,et al.  Understanding the genetic diversity of HIV-1. , 2000, AIDS.

[239]  L. Mollet,et al.  A Single Injection of Recombinant Measles Virus Vaccines Expressing Human Immunodeficiency Virus (HIV) Type 1 Clade B Envelope Glycoproteins Induces Neutralizing Antibodies and Cellular Immune Responses to HIV , 2004, Journal of Virology.

[240]  William C. Olson,et al.  Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[241]  Renate Kunert,et al.  Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies , 2005, Science.

[242]  D. Nickle,et al.  Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope , 2005, Journal of Virology.

[243]  M. Feinberg,et al.  Prospects for an AIDS vaccine: three big questions, no easy answers. , 2004, The Lancet. Infectious diseases.

[244]  J. Sodroski,et al.  Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin , 2002, Journal of Virology.

[245]  E. Ramsburg,et al.  A Single-Cycle Vaccine Vector Based on Vesicular Stomatitis Virus Can Induce Immune Responses Comparable to Those Generated by a Replication-Competent Vector , 2005, Journal of Virology.

[246]  R. Desrosiers,et al.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. , 1992, Science.

[247]  J. Cunningham,et al.  Receptor Binding Transforms the Surface Subunit of the Mammalian C-Type Retrovirus Envelope Protein from an Inhibitor to an Activator of Fusion , 2001, Journal of Virology.

[248]  Todd M. Allen,et al.  Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen1 , 2000, The Journal of Immunology.

[249]  R. Lal,et al.  Molecular and biological interactions between two HIV-1 strains from a coinfected patient reveal the first evidence in favor of viral synergism. , 2000, Virology.

[250]  R. Desrosiers,et al.  Immune evasion strategies of the primate lentiviruses , 2001, Immunological reviews.

[251]  D. Montefiori,et al.  Evaluation of Envelope Vaccines Derived from the South African Subtype C Human Immunodeficiency Virus Type 1 TV1 Strain , 2005, Journal of Virology.

[252]  A. Rahman,et al.  Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system. , 2005, Current HIV Research.

[253]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[254]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[255]  D. Price,et al.  CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[256]  R. Gallo.  Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[257]  J. Sodroski,et al.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys , 1996, Journal of virology.

[258]  A. Trkola,et al.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.

[259]  J. Mascola,et al.  Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.

[260]  D. Birx,et al.  Policy rebuttal. HIV vaccine trial justified. , 2004, Science.

[261]  P. Luciw,et al.  Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. , 1998, The Journal of general virology.

[262]  D. Watkins,et al.  Prevention of Disease Induced by a Partially Heterologous AIDS Virus in Rhesus Monkeys by Using an Adjuvanted Multicomponent Protein Vaccine , 2003, Journal of Virology.

[263]  Renate Kunert,et al.  Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. , 2005, Immunity.

[264]  Stefan H E Kaufmann,et al.  Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis , 2005, Nature Medicine.

[265]  J. Lifson,et al.  Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. , 2004, AIDS Research and Human Retroviruses.

[266]  C. Cheng‐Mayer,et al.  Increased Mucosal Transmission but Not Enhanced Pathogenicity of the CCR5-Tropic, Simian AIDS-Inducing Simian/Human Immunodeficiency Virus SHIVSF162P3 Maps to Envelope gp120 , 2003, Journal of Virology.

[267]  J. Ulmer,et al.  Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design , 2004, Expert review of vaccines.